Shanghai Medical Technology Co. Ltd. Bi was

Bi was medicine is to provide a pharmaceutical intermediates, bulk drugs, and other fine chemical products R & D and production-oriented enterprises. We mainly produce cyclization drugs, including indole, imidazole, pyrazole, pyridazine, pyridine, pyrimidine, piperazine, piperidine, thiazole, and other pharmaceutical intermediates. The company's business consists of pharmaceutical intermediates and other fine chemical products, synthetic (catalog products and custom synthesis), compound library design and synthesis, medicinal chemistry synthesis. Customers are located in the United States, Europe, Southeast Asia and other places, Including the top ten world's largest pharmaceutical companies. Our core businesses include: laboratory research and development services and production  

Show more

services. Laboratory R & D services, including product R & D Chemical Company, assay development services, and process development services, production services are primarily for the production of intermediates and bulk drugs. Bi was medicine has always attached great importance to IPR protection, both for our customers, or the company's survival and future development, intellectual property has important strategic significance. Intellectual property is the company's most valuable asset, and customerThe company has established a set of stringent documentation system to ensure cooperation partners to strictly confidential information were not disclosed: We have before the start of the experiment for customers and employees have signed confidentiality agreements, establishing a strict document management system as a means of protect customer information, including laboratory record book of daily signature files, as well as finishing work on a regular basis.